
    
      Psoriatic Arthritis participants receiving adalimumab are evaluated in a prospective,
      non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other
      week (eow), per its label. Efficacy and safety parameters are measured routinely at baseline
      and after 3, 6, 9, 12, 18 and 24 months.
    
  